Ephrin Receptor

ALW-II-49-7 is a selective inhibitor of the EphB2 kinase, exhibiting an EC50 value of 40 nM in cellular assays. It is designed to effectively disrupt EphB2 signaling pathways, which are implicated in various biological processes including cell adhesion and migration. This reagent is valuable for research applications focusing on cancer biology, neurodevelopment, and the modulation of angiogenesis.

AWL-II-38.3 is a selective inhibitor of the ephrin-A receptor (EphA3) kinase. This compound demonstrates potent inhibitory activity specifically targeting EphA3 while displaying minimal effects on Src-family kinases and b-raf. Its specificity makes AWL-II-38.3 valuable for research applications involving EphA3-mediated signaling pathways and related cellular processes.

LDN-211904 oxalate is a potent and reversible inhibitor of EphB3, exhibiting an IC50 of 79 nM. This compound demonstrates favorable metabolic stability in mouse liver microsomes, making it suitable for in vitro studies. LDN-211904 oxalate is particularly relevant for research involving STAT3-activated colorectal cancer stemness and may help overcome Cetuximab resistance in colorectal cancer.

Eph Inhibitor 1 is a potent inhibitor of Eph receptors, targeting the Eph family of receptor tyrosine kinases. It has demonstrated significant biological activity in modulating cellular signaling pathways involved in neural development and synaptic plasticity. This compound holds promise for research applications related to neurological disorders, facilitating insights into therapeutic strategies for conditions linked to Eph receptor dysregulation.

EphA2 antagonist 1 is an ephrin type-A receptor 2 (EPHA2) inhibitor designed to modulate the signaling pathways associated with this receptor. It exhibits significant biological activity in disrupting EPHA2-mediated processes, which may have implications in cancer research and metastasis studies. This compound serves as a valuable tool for investigating the role of EPHA2 in various cellular contexts and therapeutic applications.

EphB4-IN-2 is a potent tyrosine kinase inhibitor targeting EphB4, with an IC50 value of 1.6 nM in human assays. This compound demonstrates selective inhibition against kinases containing threonine gatekeeper residues, offering a high degree of ligand efficiency. Its application is valuable in research focusing on EphB4-related signaling pathways and associated therapeutic interventions.

LDN-211904 is a potent and reversible inhibitor of EphB3, with an IC50 of 79 nM, making it a valuable tool for studying EphB3-mediated signaling pathways. It demonstrates good metabolic stability in mouse liver microsomes, indicating its potential for in vivo applications. In research contexts, LDN-211904 may synergize with cetuximab to effectively inhibit STAT3 activation and address colorectal cancer stemness, as well as resistance mechanisms associated with cetuximab treatment.

ALW-II-41-27 is a novel Eph receptor tyrosine kinase inhibitor.

UniPR1331 is an orally active 3β-hydroxy-Δ5-choline acid derivative that targets Eph-ephrin interactions. By inhibiting the interaction between VEGFR2 and its ligand, vascular endothelial growth factor, UniPR1331 effectively dampens autophosphorylation, subsequent signaling, and pro-angiogenic activation in endothelial cells. This compound demonstrates significant anti-angiogenic, anti-cancer, and anti-inflammatory properties, making it suitable for research applications in cancer and inflammation, including glioma and colitis.